Potential role of the melanocortin signaling system interference in the excess weight gain associated to some antiretroviral drugs in people living with HIV

[1]  H. Stellbrink,et al.  Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  A. Vos,et al.  Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. , 2019, New England Journal of Medicine.

[3]  M. Peeters,et al.  Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1. , 2019, The New England journal of medicine.

[4]  M. Blüher.  Obesity: global epidemiology and pathogenesis , 2019, Nature Reviews Endocrinology.

[5]  A. Mocroft,et al.  Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial , 2019, PloS one.

[6]  L. Waters,et al.  Are new antiretroviral treatments increasing the risks of clinical obesity? , 2019, Journal of virus eradication.

[7]  D. Marks,et al.  Melanocortin-3 receptors expressed on agouti-related peptide neurons inhibit feeding behavior in female mice. , 2018, Obesity.

[8]  N. Ford,et al.  The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues? , 2018, AIDS.

[9]  Mark D. Ericson,et al.  Structure-Activity Relationship Studies of a Macrocyclic AGRP-Mimetic Scaffold c[Pro-Arg-Phe-Phe-Asn-Ala-Phe-DPro] Yield Potent and Selective Melanocortin-4 Receptor Antagonists and Melanocortin-5 Receptor Inverse Agonists That Increase Food Intake in Mice. , 2018, ACS chemical neuroscience.

[10]  H. Crystal,et al.  Ghrelin, Amylin, Gastric Inhibitory Peptide and Cognition in Middle-Aged HIV-Infected and Uninfected Women: The Women’s Interagency HIV Study , 2017, Alzheimer's & Dementia.

[11]  F. Villarroya,et al.  Impact of elvitegravir on human adipocytes: Alterations in differentiation, gene expression and release of adipokines and cytokines. , 2016, Antiviral research.

[12]  A. Mocroft,et al.  Short‐term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study , 2016, HIV medicine.

[13]  M. Hughes,et al.  A Randomized Comparison of Anthropomorphic Changes With Preferred and Alternative Efavirenz-Based Antiretroviral Regimens in Diverse Multinational Settings , 2015, Open forum infectious diseases.

[14]  F. Villarroya,et al.  A 48-Week Study of Fat Molecular Alterations in HIV Naive Patients Starting Tenofovir/Emtricitabine With Lopinavir/Ritonavir or Efavirenz , 2014, Journal of acquired immune deficiency syndromes.

[15]  V. Taylor,et al.  Changes in Body Weight and Psychotropic Drugs: A Systematic Synthesis of the Literature , 2012, PloS one.

[16]  F. Villarroya,et al.  HIV Type-1 Transgene Expression in Mice Alters Adipose Tissue and Adipokine Levels: Towards a Rodent Model of HIV Type-1 Lipodystrophy , 2010, Antiviral therapy.

[17]  Subhajyoti De,et al.  Common variants near MC4R are associated with fat mass, weight and risk of obesity , 2008, Nature Genetics.

[18]  R. Cone,et al.  Role of the central melanocortin circuitry in adaptive thermogenesis of brown adipose tissue. , 2007, Endocrinology.

[19]  U. Hengge,et al.  Increased neuropeptide Y-like immunoreactivity in cerebrospinal fluid and plasma of human immunodeficiency virus-infected patients: relationship to HIV encephalopathy , 1996, Journal of the Neurological Sciences.